关于 Dendreon Corporation
Dendreon Pharmaceuticals LLC is a biotechnology company. Its lead product, Provenge, is an immunotherapy for prostate cancer. It consists of a mixture of the patient's own blood cells that have been incubated with the Dendreon PAP-GM-CSF fusion protein. Phase III clinical trial results demonstrating a survival benefit for prostate cancer patients receiving the drug were presented at the AUA meeting on April 28, 2009. After going through the approval process, Provenge was given full approval by the FDA on April 29, 2010. Dendreon's stock value fell 66% on August 4, 2011, after abandoning its forecast for its debut drug Provenge.
Source: Wikipedia
总部Corporation Trust Center, 1209 Orange Street, 19801, Wilmington, US
成立2013
状态营业中
专利134 项专利
HUMORAL IMMUNE RESPONSE AGAINST TUMOR ANTIGENS AFTER TREATMENT WITH A CANCER ANTIGEN SPECIFIC ACTIVE IMMUNOTHERAPY AND ITS ASSOCIATION WITH…CA2923433C · 2020
Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with…US10261091B2 · 2019
法律信息
| 法定名称 | Dendreon Corporation |
|---|---|
| LEI | 549300C0XK81HDI8KK82在 GLEIF 上查看 ↗ |
| 注册地址 | Corporation Trust Center, 1209 Orange Street, 19801, Wilmington, US |
| 状态 | 营业中 |
来源: GLEIF · 更新于 Oct. 16, 2026
联系方式和链接
地点
Corporation Trust Center, 1209 Orange Street, 19801, Wilmington, US
这是你的公司吗?
免费认领此页面,即可添加标志、产品、照片和职位,并回复评价。
认领此页面